Eris Biotech is a biotechnology company focused on developing small-molecule drugs that reawaken the immune system to fight cancer. Eris Biotech has identified a novel pathway to block immune evasion, allowing their first-in-class oral drug to help the body's own defenses target cancer cells more effectively.
Their main product is a small-molecule inhibitor designed to be orally administered, offering safety and convenience for patients. Unlike many traditional cancer drugs that target proteins, Eris Biotech's approach does not rely on a protein target, broadening the potential patient population eligible for their therapy. This innovation aims to deliver potent cancer treatment that is accessible, safe, and easy to use at home.
What Problem Does Eris Biotech Solve?
Cancer cells often evade the body's immune response, making it difficult for patients to benefit from immunotherapies. Eris Biotech addresses this challenge by targeting a unique immune evasion pathway, enabling the immune system to recognize and attack cancer cells. By developing a small-molecule inhibitor that can be taken orally, Eris Biotech seeks to overcome limitations of current therapies that require complex administration or only benefit a subset of patients.
Who Can Benefit from Eris Biotech's Solutions?
Eris Biotech's therapies are designed for cancer patients, particularly those who may not respond to existing protein-targeted drugs or who require treatments that are easier to administer. By offering an oral, non-protein-targeted drug, Eris Biotech opens the possibility of treatment to a broader range of cancer patients.
What Makes Eris Biotech Different?
- First-in-class small-molecule inhibitor for cancer immunotherapy
- Oral administration, allowing for treatment from home
- Safe profile designed for a larger patient population
- Does not rely on protein targets, expanding eligibility
Leadership Team
Eris Biotech is led by a team with deep expertise in biotechnology and cancer research, including:
- Evita Weagel, Ph.D. (CEO)
- Andrea Mazzocchi, PhD
- Rachel Brog Garlick
- Audrey Hendley
Under Dr. Weagel's leadership, Eris Biotech has gained recognition for its disruptive work in the field, with recent awards highlighting their impact on cancer care innovation.
Use PromptLoop to Uncover Company Data
Looking for more company insights like this? PromptLoop helps you go deeper, providing unique data points and analysis on companies like Eris Biotech and many others. Automate your research and find the information that matters most. Discover how PromptLoop can accelerate your market intelligence. Get A Free Demo to learn more.